Recent blog posts
Aniridia, Partial, With Unilateral Renal Agenesis and Psychomotor Retardation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Aniridia, Partial, With Unilateral Renal Agenesis and Psychomotor Retardation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Aniridia, Partial, With in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Urogenital Abnormalities Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Urogenital Abnormalities Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Urogenital Abnormalities in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Optic Neuropathy, Ischemic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Optic Neuropathy, Ischemic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Optic Neuropathy, Ischemic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Combined pulmonary fibrosis and emphysema Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Combined pulmonary fibrosis and emphysema Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Combined pulmonary fibrosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Cholestasis-edema syndrome, Norwegian type Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Cholestasis-edema syndrome, Norwegian type Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Cholestasis-edema syndrome in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Bronchogenic Carcinoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Bronchogenic Carcinoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Bronchogenic Carcinoma in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Ichthyosis, Lamellar Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Ichthyosis, Lamellar Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Ichthyosis, Lamellar with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Autosomal recessive ichthyosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Autosomal recessive ichthyosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Autosomal recessive ichthyosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Rickets, Hypophosphatemic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Rickets, Hypophosphatemic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Rickets, Hypophosphatemic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Purpura, Thrombocytopenic, Idiopathic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Purpura, Thrombocytopenic, Idiopathic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Purpura, Thrombocytopenic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Lung Cancer Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Lung Cancer Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Lung Cancer with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Alopecia, Epilepsy, Pyorrhea, Mental Subnormality Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Alopecia, Epilepsy, Pyorrhea, Mental Subnormality Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Alopecia, Epilepsy, Pyorrhea in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →